Reserpine-induced decrease in type I and II corticosteroid receptors in neuronal and lymphoid tissues of adrenalectomized rats.
The effect of the biogenic amine depleting drug, reserpine, on the concentration of type II corticosteroid receptors (i.e., glucocorticoid receptors) in neuronal (hippocampus, frontal cortex, hypothalamus), lymphoid (circulating lymphocytes, spleen, thymus) and pituitary tissues as well as hippocampal type I (i.e., mineralocorticoid) receptors was examined in adrenal-intact and adrenalectomized (ADX) rats. Reserpine (2 mg/kg) or vehicle was administered to adrenal-intact rats for 2 consecutive days. Following the second injection rats were ADX and sacrificed 24 h later. Reserpine significantly decreased type I and II hippocampal receptors as well as type II receptors in frontal cortex, hypothalamus, lymphocytes and spleen. Since the reserpine-induced decreases in receptor content could be due to reserpine-induced elevations in circulating corticosterone levels, reserpine (2 mg/kg) or vehicle was administered to 1-day ADX rats which were then sacrificed 2 days later (i.e., 3 days post ADX). A 1-day ADX control group was also included. The 3-day ADX regimen produced significant or nearly significant increases in type II receptors in hippocampus, frontal cortex, hypothalamus, lymphocytes and spleen in vehicle-treated rats. Reserpine attenuated the ADX-induced upregulation of type II receptors in hippocampus, frontal cortex, lymphocytes and spleen, but had no effect on the ADX-induced upregulation of type II receptors in the hypothalamus. The ADX-induced increase in hippocampal type I receptors was not affected by reserpine treatment. In a final experiment, reserpine (2 mg/kg) or vehicle was administered immediately after ADX and rats were sacrificed 24 h later in order to assess the effect of reserpine on basal (i.e., nonupregulated) corticosteroid receptor levels in the absence of circulating corticosterone levels.(ABSTRACT TRUNCATED AT 250 WORDS)
Lowy
M T
MT
Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio.
D000315:Adrenalectomy; D000818:Animals; D001921:Brain / Q000187:drug effects*; D001923:Brain Chemistry; D005625:Frontal Lobe / Q000032:analysis / Q000187:drug effects; D006624:Hippocampus / Q000032:analysis / Q000187:drug effects; D007031:Hypothalamus / Q000032:analysis / Q000187:drug effects; D008214:Lymphocytes / Q000032:analysis / Q000187:drug effects; D008221:Lymphoid Tissue / Q000032:analysis / Q000187:drug effects*; D008297:Male; D009474:Neurons / Q000032:analysis / Q000187:drug effects*; D010902:Pituitary Gland / Q000032:analysis / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D011965:Receptors, Glucocorticoid / Q000032:analysis / Q000187:drug effects*; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid / Q000032:analysis / Q000187:drug effects*; D012110:Reserpine / Q000494:pharmacology*; D013154:Spleen / Q000032:analysis / Q000187:drug effects; D013950:Thymus Gland / Q000032:analysis / Q000187:drug effects
D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid; D012110:Reserpine